Cizzle Biotechnology to offer early lung cancer tech throughout the USA (VIDEO)

Cizzle Biotechnology Holdings plc (LON:CIZ) Executive Chairman, Allan Syms joins DirectorsTalk Interviews to discuss an agreement with CorePath Laboratories to develop and offer its proprietary early-stage lung cancer test throughout the USA.

Allan explains what the partnership will cover, provides us with more information on CorePath Laboratories and what they do, explains how Cizzle’s proprietary detection test can potentially help sufferers and how the company is developing in other areas and what the rest of the year holds for the company.

Cizzle Biotechnology is a UK based developer of a blood test for the early detection of a majority of different forms of lung cancer.

You might also enjoy reading  Cizzle Biotechnology update on development of proprietary antibodies

Share this interview

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on whatsapp